You just read:

Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators

News provided by

Entest BioMedical Inc.

Jul 26, 2017, 09:45 ET